Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | SLC9A3 | P48764 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9254492 | 0.75 | CHRNA7 (0.40) | TSHRCHRNA7SLC9A3CYP2D6LMNA | |
| SCHEMBL18634398 | 0.69 | CHRNA7 (0.53) | TSHRCHRNA7OPRM1OPRK1 | |
| SCHEMBL21142551 | 0.67 | CHRNA7 (0.74) | TSHRCHRNA7OPRM1OPRK1SIGMAR1 | |
| SCHEMBL3402404 | 0.67 | CHRNA7 (0.74) | TSHRCHRNA7OPRM1OPRK1SIGMAR1 | |
| SCHEMBL1828684 | 0.67 | TSHR (0.45) | TSHRCHRNA7SLC9A3CYP2D6CYP2C19 | |
| SCHEMBL6613669 | 0.66 | HTR2A (0.37) | CYP2D6CYP2C19 | |
| SCHEMBL11194889 | 0.66 | TSHR (0.51) | TSHRCHRNA7 | |
| SCHEMBL11193476 | 0.66 | TSHR (0.51) | TSHRCHRNA7 | |
| SCHEMBL11198053 | 0.66 | TSHR (0.51) | TSHRCHRNA7 | |
| SCHEMBL11620522 | 0.66 | FYN (0.59) | TSHRCHRNA7CYP2D6CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | TSHR 931/4885CHRNA7 2591/4885SLC9A3 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.